Forecast

Buy	2
Hold	0
Sell	0

News Go to news feed

LANXESS ramps up cost cuts and deleveraging as markets remain weak

LANXESS is accelerating cost reductions, portfolio shifts and debt-reduction measures as weak agriculture and construction markets pressure earnings. Its FORWARD! program has delivered about €150 million in savings with ~€170 million more planned through 2028, including plant closures and capacity shifts toward pharmaceuticals. Q2 adjusted EBITDA rose to €152 million and free cash flow turned positive, but management kept 2026 EBITDA pre guidance at €450–550 million and warned the improvement may not be a trend. The company targets net debt below 2.5x EBITDA and plans tighter capital and working-capital management plus monetization of its Envalior stake to restore investment-grade status. » More on finance.yahoo.com
Lanxess strengthens resilience through cost cuts and portfolio restructuring

At the German Select VIII Conference Lanxess reported an improvement in Q2 with adjusted EBITDA of €152m (Q1: €94m) and positive free cash flow of €56m. The company confirms its full-year adjusted EBITDA guidance of €450–550m and expects Q3 EBITDA of €130–150m. Management stresses that cost reductions and a focus on the portfolio remain the main drivers of earnings stabilization, as capacity utilization at around 65–70% is still below a healthy level. Lanxess is prioritizing debt reduction, including possible monetization of its Envalior stake, plans further savings and no major capacity expansions. » More on de.investing.com
Lanxess falls after downgrades, hits lowest level since March

Lanxess shares lost about five percent, falling to €13.96 — their lowest level since March — triggering another sell signal. BNP Paribas Exane downgraded the stock to “Underperform” and cut the target price to €12.00; previously Berenberg had also substantially reduced its target and issued a “Sell” vote. Weighing on the stock are logistics problems caused by low water levels in the Rhine; the share is currently one of the biggest losers in the MDAX. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Lanxess has already paid 0,10€ in dividends. The last payout was in May.

Financials

In the last quarter, Lanxess had revenue of 1.56b€ and net profit of −53.00m€

(EUR)	Jun 2026	YoY
Revenue	+1.56b	6,48%
Gross profit	+330.00m	0,92%
Net profit	−53.00m	17,78%
EBITDA	+96.00m	44,19%

Fundamentals

Metric	Value
Market capitalization	+1.22b€
Number of shares	86.35m
52-week high/low	+25,46€ - +11,03€
Dividend yield	+0,70%
Dividends TTM	+0,10€
Beta	1,15
P/E ratio	−1,83
PEG ratio	+0,02
P/B ratio	+0,35
P/S ratio	+0,22

Company profile

Der Spezialchemie-Konzern LANXESS Aktiengesellschaft entwickelt, produziert und vermarktet weltweit chemische Zwischenprodukte, Additive, Spezialchemikalien und Kunststoffe. Das Unternehmen ist in vier Segmenten tätig: Advanced Intermediates, Specialty Additives, Consumer Protection und Engineering Materials. Das Segment Advanced Intermediates bietet fortschrittliche industrielle Zwischenprodukte, Grund- und Feinchemikalien, Organometalle und anorganische Pigmente für die Agrochemie-, Automobil-, Bau-, Aromen- und Geschmacksstoff-, Halbleiter- und Photovoltaik- sowie Farbpigmentindustrie. Das Segment Specialty Additives bietet Additive an, darunter Schmiermittel, Flammschutzmittel, Weichmacher und Bromderivate für verschiedene Anwendungen in der Gummi-, Kunststoff-, Farben-, Bau- und Elektroindustrie. Das Segment Consumer Protection bietet Materialschutzprodukte, Desinfektions-, Hygiene- und Konservierungslösungen, Aromen und Duftstoffe sowie Vor- und Zwischenprodukte für die Agro-, Pharma- und Spezialchemieindustrie und Technologien zur Aufbereitung von Wasser und anderen Flüssigkeiten. Das Segment Engineering Materials produziert technische Kunststoffe, Glasfasern, Faserverbundwerkstoffe und Elastomere auf Urethanbasis für Anwendungen in der Automobil- und Elektro-/Elektronikindustrie, im Bauwesen, in der Medizin sowie im Sport- und Freizeitbereich. Das Unternehmen wurde 1863 gegründet und hat seinen Hauptsitz in Köln, Deutschland.